This company has been marked as potentially delisted and may not be actively trading. Travere Therapeutics (RTRX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock RTRX vs. MOR, GMTX, CALT, ZYME, SBTX, MBX, NLTX, CYBN, BIOA, and VIRIShould you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include MorphoSys (MOR), Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Silverback Therapeutics (SBTX), MBX Biosciences (MBX), Neoleukin Therapeutics (NLTX), Cybin (CYBN), BioAge Labs (BIOA), and Virios Therapeutics (VIRI). Travere Therapeutics vs. Its Competitors MorphoSys Gemini Therapeutics Calliditas Therapeutics AB (publ) Zymeworks Silverback Therapeutics MBX Biosciences Neoleukin Therapeutics Cybin BioAge Labs Virios Therapeutics Travere Therapeutics (NASDAQ:RTRX) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings. Which has better valuation and earnings, RTRX or MOR? Travere Therapeutics has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTravere Therapeutics$175.34M5.13-$146.43M-$3.46-5.10MorphoSys$238.28M11.99-$205.35M-$3.48-5.45 Is RTRX or MOR more profitable? Travere Therapeutics has a net margin of -49.13% compared to MorphoSys' net margin of -226.79%. Travere Therapeutics' return on equity of -36.38% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets Travere Therapeutics-49.13% -36.38% -14.90% MorphoSys -226.79%-694.31%-22.55% Do insiders & institutionals hold more shares of RTRX or MOR? 18.4% of MorphoSys shares are held by institutional investors. 4.6% of Travere Therapeutics shares are held by insiders. Comparatively, 0.1% of MorphoSys shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media refer more to RTRX or MOR? In the previous week, Travere Therapeutics' average media sentiment score of 0.00 equaled MorphoSys'average media sentiment score. Company Overall Sentiment Travere Therapeutics Neutral MorphoSys Neutral Which has more risk and volatility, RTRX or MOR? Travere Therapeutics has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. SummaryTravere Therapeutics beats MorphoSys on 6 of the 11 factors compared between the two stocks. Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RTRX vs. The Competition Export to ExcelMetricTravere TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$900.05M$813.47M$5.75B$9.58BDividend YieldN/A4.84%4.54%4.09%P/E Ratio-8.361.1530.3824.94Price / Sales5.1325.62415.42178.09Price / CashN/A19.5637.3459.16Price / Book3.426.528.936.27Net Income-$146.43M-$4.93M$3.26B$265.47M Travere Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RTRXTravere TherapeuticsN/A$17.63-6.1%N/A+116.2%$900.05M$175.34M-8.36221High Trading VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730Positive NewsGMTXGemini TherapeuticsN/A$58.59+1.0%N/A+22.7%$2.54BN/A-58.5930CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks1.7757 of 5 stars$13.02+4.7%$21.43+64.6%+34.4%$907.27M$122.87M-8.68460SBTXSilverback TherapeuticsN/A$16.38-6.4%N/A-1.5%$590.63MN/A-6.7783News CoveragePositive NewsHigh Trading VolumeMBXMBX Biosciences2.5623 of 5 stars$12.53+11.3%$37.63+200.3%N/A$378.27MN/A-2.7636News CoverageGap DownNLTXNeoleukin TherapeuticsN/A$20.35-4.1%N/A-41.6%$191.25MN/A-6.5490High Trading VolumeCYBNCybin2.4419 of 5 stars$7.63+5.1%$85.00+1,014.0%N/A$171.26MN/A-1.7450Trending NewsAnalyst RevisionBIOABioAge LabsN/A$4.48+3.2%N/AN/A$155.59M$3.86M0.00N/AVIRIVirios TherapeuticsN/A$4.77-2.5%$5.00+4.8%+2,617.9%$91.86MN/A-17.675Gap Down Related Companies and Tools Related Companies MorphoSys Alternatives Gemini Therapeutics Alternatives Calliditas Therapeutics AB (publ) Alternatives Zymeworks Alternatives Silverback Therapeutics Alternatives MBX Biosciences Alternatives Neoleukin Therapeutics Alternatives Cybin Alternatives BioAge Labs Alternatives Virios Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RTRX) was last updated on 8/20/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access